Literature DB >> 14673382

Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models.

Dennis Huugen1, Jan Willem Cohen Tervaert, Peter Heeringa.   

Abstract

PURPOSE OF REVIEW: Since the discovery of antineutrophil cytoplasmic autoantibodies (ANCA) and their association with the occurrence of several types of small-vessel vasculitis, a causal relation between the two has been suggested. Various in vitro and in vivo experimental data provide indirect evidence in support of this view. This article comprises a review of the animal models that have been used to investigate the pathogenesis of ANCA-associated vasculitis, and focuses on recent developments in this field. RECENT
FINDINGS: Xiao et al. provide definite proof of the pathogenic potential of ANCA in a novel mouse model of myeloperoxidase (MPO)-ANCA-associated vasculitis, in which transfer of splenocytes or IgG from MPO-/- mice immunized with murine MPO, to naive wild-type or Rag2-/- (lacking mature B and T lymphocytes) mice causes a disease remarkably similar to its human counterpart. In addition, preliminary studies by Smyth et al. show that immunization of Wistar Kyoto rats with human MPO induces antihuman MPO antibodies that cross-react with rat MPO, as well as a disease closely resembling human small-vessel vasculitis. Another murine ANCA model is the SCG/Kj mouse. A recent publication by Neumann et al., however, puts an important limitation on the use of this mouse model for the study of ANCA-associated vasculitis, demonstrating multiple immune complex deposits in the spontaneously occurring vascular lesions. SUMMARY Recently developed animal models of MPO-ANCA-associated vasculitis convincingly demonstrate that MPO-ANCA are pathogenic. Whether similar strategies can be used to develop an appropriate model for proteinase 3-ANCA-associated vasculitis remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673382     DOI: 10.1097/00002281-200401000-00003

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  5 in total

Review 1.  Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Authors:  O Flossmann; R B Jones; D R W Jayne; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

2.  Animal models of vasculitides.

Authors:  Uriel Katz; Boris Gilburd; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 3.  Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides.

Authors:  Ora Shovman; Boris Gilburd; Gisele Zandman-Goddard; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

4.  Immunomodulation with eicosapentaenoic acid supports the treatment of autoimmune small-vessel vasculitis.

Authors:  Junichi Hirahashi; Kimito Kawahata; Makoto Arita; Ryo Iwamoto; Keiichi Hishikawa; Mie Honda; Yoshifumi Hamasaki; Mototsugu Tanaka; Koshu Okubo; Miho Kurosawa; Osamu Takase; Masanori Nakakuki; Kan Saiga; Kazuo Suzuki; Shoji Kawachi; Akihiro Tojo; George Seki; Takeshi Marumo; Matsuhiko Hayashi; Toshiro Fujita
Journal:  Sci Rep       Date:  2014-09-18       Impact factor: 4.379

5.  Laboratory Standard in the Diagnosis and Therapy Monitoring of Autoimmune Disease: Vasculitis.

Authors:  Branko Malenica
Journal:  EJIFCC       Date:  2006-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.